Antidepressant effects of ketamine in depressed patients.

By R. Berman, A. Cappiello, A. Anand, D. Oren, G. Heninger, Dennis S. Charney, John H. Krystal. Biological Psychiatry, 2000

3,603 citations recorded by the source corpus.

Subfields: Biological Psychiatry, Cellular and Molecular Neuroscience, Pharmacology

View Paper: https://www.semanticscholar.org/paper/acb841616901f46541384f2bca2579c68e814a48

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biological Psychiatry

In Cellular and Molecular Neuroscience

In Pharmacology

Citations in the corpus

NMDA Receptor Blockade at Rest Triggers Rapid Behavioural Antidepressant Responses (2011, methodology): “Representative field-potential traces (average 2 min) are shown during baseline (1) and at 45 min (2).”
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework (2014, background): “Although clinical validation was not confirmed in the Phase IIa studies, retrospective analysis suggested that AZD1981 showed limited efficacy in an atopic/allergic asthma population selected by a positive skin prick test.”
The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis (2017, neutral): “(10) 8 5 Outpatient Saline Major depression 0 0”
Altered connectivity in depression: GABA and glutamate neurotransmitter deficits and reversal by novel treatments (2019, background): “, 40 min) leads to a rapid (80 min) and sustained (up to 7 d) antidepressant response even in patients considered treatment resistant (Berman et al., 2000; Zarate et al., 2006).”
Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. (2010, neutral): “The two published reports of V ketamine as a potential rapid intervention for MDD inluded IV saline as an inactive placebo control (5,6).”
The cellular neurobiology of depression (2001, background): “Current research is examining the potential efficacy of antagonists of corticotropin-releasing factor (CRF), antiglucocorticoids and direct and indirect glutamate antagonist”
Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial (2013, positive): “71 for MADRS scores and response rates of 60% versus 15% for ketamine and midazolam, respectively, were derived from previous reports (11, 12).”
NMDAR inhibition-independent antidepressant actions of ketamine metabolites (2016, neutral): “ketamine studies: 238 → 125 (ketamine); 224 → 125 (norketamine); 222 → 177 (dehydronorketamine); 240 → 125 (HNK); 254 → 151 (HK) and (R,S)-d2-ketamine studies: 240 → 125 (d2-ketamine); 226 → 125 (d2-norketamine); 223 → 178 (ddehydronorketamine); 241 → 125 (d-(2,6)-HNK); 242-125 (d2-(2,5)-HNK);(d2-(2”
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial (2017, neutral): “Oropharyngeal pain 2 (6) 0 1 (5) 2 (12) 3 (5)”
Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications (2013, background): “…monoaminergic systems and the hypothalamic-pituitary adrenal (HPA)-axis, changes in growth factors and neuropeptides, alterations in glutamate neurotransmission, and decreased neurogenesis (Heim et al., 1997, Charney, 1998, Berman et al., 2000, Pariante and Miller, 2001, Duman and Monteggia, 2006).”
A Randomized Add-on Trial of an N-methyl-d-aspartate Antagonist in Treatment-Resistant Bipolar Depression (2010, neutral): “Lithium 7 (39) 16 (89) Antidepressants Duloxetine 7 (39) 13 (72) SSRI 6 (33) 18 (100) Bupropion 5 (28) 16 (89) Venlafaxine 2 (11) 11 (61) Trazodone 2 (11) 7 (39) MAOI 1 (6) 7 (39) TCA 0 7 (39) Mirtazapine 0 6 (33) Nefazodone 0 3 (17) Antipsychotics Quetiapine 9 (50) 16 (89) Aripiprazole 2 (11) 10 (5”